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Abstract
Central neurocytomas are uncommon intraventricular neoplasms whose optimal management 
remains controversial due to their rarity. We assessed outcomes for a historical cohort of 
neurocytoma patients and evaluated effects of tumor atypia, size, resection extent, and adjuvant 
radiotherapy. Progression-free survival (PFS) was measured by Kaplan–Meier and Cox 
proportional hazards methods. A total of 28 patients (15 males, 13 females) were treated between 
1995 and 2014, with a median age at diagnosis of 26 years (range 5–61). Median follow-up was 
62.2 months and 3 patients were lost to follow-up postoperatively. Thirteen patients experienced 
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recurrent/progressive disease and 2-year PFS was 75 % (95 % CI 53–88 %). Two-year PFS was 
48 % for MIB-1 labeling >4 % versus 90 % for ≤4 % (HR 5.4, CI 2.2-27.8, p = 0.0026). Nine 
patients (32 %) had gross total resections (GTR) and 19 (68 %) had subtotal resections (STR). PFS 
for >80 % resection was 83 versus 67 % for ≤80 % resection (HR 0.67, CI 0.23–2.0, p = 0.47). 
Three STR patients (16 %) received adjuvant radiation which significantly improved overall PFS 
(p = 0.049). Estimated 5-year PFS was 67 % for STR with radiotherapy versus 53 % for STR 
without radiotherapy. Salvage therapy regimens were diverse and resulted in stable disease for 
54 % of patients and additional progression for 38 %. Two patients with neuropathology-
confirmed atypical neurocytomas died at 4.3 and 113.4 months after initial surgery. For central 
neurocytomas, MIB-1 labeling index >4 % is predictive of poorer outcome and our data suggest 
that adjuvant radiotherapy after STR may improve PFS. Most patients requiring salvage therapy 
will be stabilized and multiple modalities can be effectively utilized.
Keywords
Central neurocytoma; Intraventricular neurocytoma; Benign central nervous system tumor; 
Progression free survival; MIB-1 labeling index
Introduction
Central neurocytomas or intraventricular neurocytomas (IVNs) are rare central nervous 
system tumors derived from ectodermal/nervous system tissue [1]. These tumors are 
typically benign, though atypical variants have been reported and residual postsurgical tumor 
is believed to have potential for malignant transformation [2]. The rarity of central 
neurocytomas, which comprise only 0.1–0.5 % of all primary brain tumors [3, 4], has 
resulted in a paucity of information regarding their optimal management [5]. Typically, 
neurocytomas carry favorable prognoses, but can exhibit more aggressive clinical behavior 
[5]. Seventy percent of patients present between age 20 and 40 years. Tumor incidence 
shows minimal gender predominance [3].
Patients frequently present with neurological symptoms such as headaches and/or visual 
changes, with a duration of clinical symptoms typically less than 6 months [5]. CT scans 
generally demonstrate a slightly hyperdense mass within the body of the lateral ventricles 
[3]. MRI reveals a peri-ventricular mass that can be isointense or hypointense on T1-
weighed images and isointense or hyperintense on T2-weighed images [6–8]. Post 
gadolinium contrast appearance can be variable, though most tumors demonstrate moderate 
to strong enhancement [7]. Intracranial angiography is rarely performed.
Central neurocytomas with anaplastic or atypical pathologic features behave more 
aggressively and might be associated with greater local relapse [9, 10]. One objective marker 
is MIB-1; however, the specific threshold suggesting atypia is debated [9, 11–16].
Modern management of neurocytomas has been guided by several institutional case series 
[4, 17–19]. Surgical resection is the primary treatment to establish pathologic diagnosis, to 
clear CSF pathways and to address any obstructive hydrocephalus [5]. Most studies support 
the idea that complete resection is an important predictor of recurrence [16, 18, 20, 21]; 
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however, this fact remains unclear since other reports have not identified significant 
improvements in survival or local control [10, 17].
Adjuvant radiotherapy (RT) after gross total resection (GTR), particularly for typical 
neurocytoma, remains controversial since most patients have long-term tumor control [22–
25]. Primary radiosurgery has been used for neurocytoma, and reduction of tumor volume 
was reported [26], without radiosurgical complications [27]. Adjuvant radiotherapy is 
frequently offered to patients with incomplete resections or evidence of atypia and options 
include stereotactic radiosurgery (SRS) or fractionated external beam radiotherapy (EBRT) 
[10]. Chemotherapy options, as part of multimodal treatment, typically include carmustine, 
prednisone, vincristine, and cisplatin, although responses to chemotherapy have not been 
well-characterized [28].
Given the numerous aspects of neurocytoma clinical management that remain unclear, we 
reviewed our institution's experience. In our study, we summarize 20 years of treatment 
approach to investigate whether extent of resection, MIB-1 labeling index, adjuvant 
radiotherapy and initial tumor size influence clinical outcomes.
Methods and materials
Existing pathology and neurosurgery databases were searched using keywords designed to 
identify all patients with neurocytomas treated at the University of California at San 
Francisco (UCSF) between 1994 and 2014. Prospective patients were next evaluated against 
a number of inclusion criteria: (1) initial surgery was performed at UCSF, (2) initial 
treatment record was available, and (3) confirmatory pathology was available in the medical 
record. Given the rarity of this tumor, we included all patients irrespective of follow-up 
duration. The medical records were reviewed and the following data were collected: 
demographic information, initial and salvage treatment approach, and outcomes. This study 
was approved by the UCSF Institutional Review Board.
All cases included in this series underwent a central pathologic re-review by a single 
neuropathologist (TT). Tumor dimensions were measured on T1 post-contrast and T2-
weighted brain MRI in the transverse, antero-posterior, and vertical directions, and the 
product of these three diameters was used as a surrogate for the tumor volume. Initial tumor 
size was considered as the maximum length of the three orthogonal dimensions on the 
patient's pre-operative planning MRI image. Degree of resection was determined by 
reviewing the operative notes and post-operative imaging and/or neuroradiology reports. All 
complete resections and near-total resections defined radiologically were classified as GTR, 
with all other surgical procedures, including biopsy with cyst aspiration, considered as 
subtotal resection (STR).
Outcomes of interest included progression free survival (PFS) and overall survival (OS) both 
from the date of first surgery. If progression was not documented, patients were assumed to 
be progression-free and censored upon the last day of recorded contact. Patients were 
followed clinically and with imaging studies (MRI and/or CT) performed during follow-up 
period at the discretion of the treating neuro-oncologist and were not done at uniform 
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intervals for all patients. Tumor progression was defined as ≥25 % increase of the 
aforementioned radiologic tumor volume estimate.
Statistical analysis
Descriptive statistics were employed to characterize the patient cohort. The Kaplan–Meier 
method was used to estimate median progression-free survival and overall survival. We used 
the log-rank test and univariate Cox proportional hazards methods to assess how prognostic 
factors, such as extent of resection, tumor size, MIB-1 labeling index, and adjuvant 
radiotherapy impacted PFS and OS. Threshold for statistical significance was p ≤ 0.05.
Results
Patient demographics
A total of 28 patients with pathologically proven central neurocytomas were treated and 26 
of these patients were alive at time of analysis (Table 1). Three patients were lost to follow-
up after initial surgical resection but were still included in the initial descriptive analysis. 
Male to female ratio was 1.15:1. Median age at diagnosis was 26 years (range 5–61 years). 
Most patients (86 %) had tumors centered within a lateral ventricle, 3 (11 %) had midline 
ventricular lesions and 1 had a parietal mass. None of the patients had MRI evidence of 
spinal drop metastases and 1 patient had evidence of CSF disease spread at initial diagnosis 
based on a lumbar puncture with positive cytology. Histopathologically, all tumors were 
classified as WHO Grade II. Seven of the 28 tumors (25 %) were noted as atypical by our 
neuropathologist. As assessed by pre-operative MRI, median maximal tumor diameter was 
4.1 cm (range 0.8–8.6 cm). Figure 1 shows representative MRI findings from our series.
All patients underwent at least one craniotomy for definitive diagnosis and surgical 
resection. Initial surgical approach was available for 24 patients, with the most common 
approaches being transcortical transventricular (39 %) and interhemispheric transcallosal 
(29 %). Three patients (11 %) underwent staged resection with different approaches in 
separate surgeries. Median extent of initial resection was 85 % (range 30–100 %). Thirty-
two percent of patients (9/28) had GTR, and 68 % (19/28) had STR. Nearly 40 % (11/28) of 
patients had persistent hydrocephalus that required placement of a ventriculoperitoneal 
shunt, placed an average of 31 days (range 5–96 days) after initial surgery. Two of these 
patients required at least one shunt revision.
One patient who underwent a GTR received adjuvant external beam radiotherapy (EBRT). 
Three STR patients (14 %) received adjuvant radiotherapy after initial resection, of which 
two underwent EBRT and the remaining patient had stereotactic radiosurgery. The 
remaining 25 patients did not receive adjuvant therapy.
Outcomes
Median duration of follow-up for the cohort was 62.2 months (range 0.03–237.7 months). 
Over the time period of our analysis, thirteen patients (46 %) developed recurrent or 
progressive disease whereas the remaining members of the cohort did not have evidence of 
progressive disease at last recorded interaction. We report two total cohort deaths (7 %).
Imber et al. Page 4
J Neurooncol. Author manuscript; available in PMC 2017 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Overall actuarial 2-year PFS was 75 % and estimated 5-year PFS was 54 % (Table 2). 
Neither age nor gender significantly impacted PFS. In terms of tumor size, actuarial 2-year 
PFS was 82 % for tumors >4.1 cm and 75 % for tumors ≤4.1 cm (HR 1.2, CI 0.37–3.6, p = 
0.80) (Fig. 2a). In terms of extent of resection, actuarial 2-year PFS for patients with >80 % 
resection was 83 versus 67 % for ≤80 % resection (HR 0.67, CI 0.2–2.0, p = 0.47) (Fig. 2b). 
Patients who had a staged resection compared to a single operation did not have significantly 
different outcomes.
Regarding tumor atypia, 2-year PFS was 90 % for MIB labeling ≤4 versus 48 % for MIB 
labeling >4 % (HR 5.4, CI 2.2–27.8, p = 0.0026) (Fig. 2c). Mean initial MIB-1 index for 
patients with progressive/recurrent disease was 4.5 % compared to 2.7 % for patients who 
did not progress/recur (p = 0.061, unpaired t test). Finally, we assessed the impact of 
adjuvant radiotherapy and found that the overall PFS improvement for subtotally resected 
patients who received adjuvant radiation was significant with p = 0.049 (Fig. 2d).
Five-year overall survival (OS) for all patients was 96 %, and estimated 10-year OS was 
82 %. For the two cohort deaths, one occurred 4.3 months after initial surgery and was 
attributed to complications of a peri-operative intracranial hemorrhage in the context of a 
salvage operation for progressive disease. The second death occurred 113.4 months after 
initial surgery and was attributed to progressive neurocytoma. These patients both had 
evidence of tumor atypia, with initial MIB-1 indices of 6.8 and 7.7 %, respectively.
Post-progression management
Several management strategies were utilized for the 13 patients with progressive or recurrent 
neurocytoma. Four patients (29 %) received salvage chemotherapy. One patient who was 
treated with 6 rounds of CCNU had robust radiographic response with subsequent stable 
disease at 3.2 years post salvage. Two patients were treated with temozolomide, one of 
whom had roughly three years of tumor stabilization before developing subtle progression. 
The other continued to have slow progressive tumor growth while on chemotherapy. At last 
follow-up, both patients were alive with disease.
Four patients (29 %) had repeat surgery and an additional patient had repeat surgery plus 
temozolomide. Two of these patients had perioperative intracranial hemorrhages and one 
patient died from this complication. The remaining four patients who received salvage 
surgery had stable disease at date of last encounter with median duration of 27 months after 
salvage surgery (range 4–63 months).
Two patients (21 %) had salvage radiosurgery, both of whom had radiographic evidence of 
treatment response. One patient received single fraction SRS to two small areas of 
recurrence each less than 1 cc of volume and received 16 Gy to each lesion. The second 
patient received a total of 30 Gy for a larger ventricular recurrence, delivered by fractionated 
frameless radiosurgery in five, 6 Gy fractions. Both patients had evidence of treatment effect 
with no new disease at date of last follow-up, 17 and 34 months after receiving salvage 
radiotherapy, respectively.
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Discussion
In our historical cohort of benign central neurocytoma, we report a five-year PFS of 54 % 
with OS of 96 %. The tumor's rarity makes it challenging to define standards of care; 
however, most institutions, including our own, recommend resection as first line therapy 
[29]. Most patients will have favorable outcomes; however, clear risk factors for poorer 
prognosis are emerging. Specifically, a pooled analysis of over 400 patients has 
demonstrated that GTR is superior to STR and that atypical lesions have poorer local control 
and OS compared to typical variants [29]. It is now well established that a higher MIB-1 
labeling index is associated with more aggressive behavior [9, 11]. In our series, all but four 
tumors were stained for MIB-1 (range = 0.5–7.7 %) with a higher mean index in patients 
who recurred. This difference trended towards significance (p = 0.061), likely the 
consequence of small sample size. Proposed treatment algorithms have started to incorporate 
MIB-1 as a consideration as to whether or not a patient should receive adjuvant therapy 
following STR [13, 30]. However, the pathological classification of “atypical neurocytoma” 
broadly, and specifically which MIB-1 levels portend poorer outcomes remain uncertain. 
Some of the first case series to recognize the association between MIB-1 labeling index and 
risk of recurrence proposed >2 % as a marker of atypical behavior [11, 13]. In our series, 
MIB-1 index of >2 % is suggestive of poorer outcome but it did not reach traditional levels 
of significance. Other studies have also found no correlation between MIB-1 and recurrence 
risk, suggesting that perhaps 2 % is too conservative [31]. A meta analysis performed about 
a decade ago proposed a higher threshold, suggesting that >3 % is associated with higher 
rates of local recurrence and poorer OS [15]. In our study, tumors with initial MIB-1 indices 
above 4 % were found to have significantly higher risk of progression. This finding aligns 
with other series that propose higher thresholds for atypical behavior [16]. Regardless of the 
threshold, consensus exists that adjuvant therapy should be strongly considered for tumors 
with higher MIB-1 indices.
Most cohort patients were not able to undergo GTR underscoring the technical challenge of 
removing intraventricular lesions. Very extensive ventricular tumors, or those that extend 
into the third ventricle, may require staged approaches via anterior and posterior routes. 
Interestingly, in our series, greater extent of initial resection and smaller initial tumor size 
did not appear to correlate with improved local control. While most prior case series [18, 29, 
32] assert that incomplete resection is associated with increased recurrence, this finding is 
inconsistent. A recent retrospective study of 45 central neurocytoma patients reported no 
significant difference in local control or survival between GTR and STR, but found local 
control and survival advantages in patients with lower mitotic indices [17]. This study was 
confounded by the fact that one-third of the population received adjuvant radiation. In a 
recent systematic review, resection extent was not predictive of improved local control [10]. 
Our cohort may be too small to assess true outcome differences between STR and GTR.
Three patients underwent adjuvant radiotherapy after STR ranging from 70 to 95 %; 
however, MIB-1 did not guide that decision. In fact, two tumors did not have staining 
available since they were resected prior to the early published correlations between MIB-1 
and recurrence risk [11]. Acknowledging the inherent limitation of low patient numbers, our 
data suggest there may be improved local control for the small subcohort that underwent 
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adjuvant radiotherapy compared to those that did not. Numerous reports are emerging which 
suggest that adjuvant radiotherapy can significantly improve local control, and some also 
note OS improvements [33].
The appropriate treatment of recurrent disease remains ambiguous, with options including 
re-operation, EBRT, SRS and/or chemotherapy [34]. Even within our series, the diversity of 
salvage treatment modalities underscores the heterogeneity of management. The use of 
image guided craniotomy has allowed for directed approaches for small tumors typically 
high in the ventricle along the wall opposite the original surgical approach. Anecdotally, we 
report two patients whose recurrent disease regressed following SRS. Genc et al. have 
published the largest series examining utilization of SRS for residual or recurrent 
neurocytomas and reported after a mean of almost 37 months of follow-up, durable 
reduction in tumor size for 15/22 patients, stable disease in 6/22 and one patient with 
progressive disease [14]. They reported a trend towards better response in tumors with lower 
MIB-1; however, these results were not significant and were attributed to short follow-up 
time. A recent systematic review concluded that both fractionated EBRT and SRS represent 
reasonable options for recurrent or residual tumors, and found a statistically non-significant 
trend towards better local tumor control and survival rates with fewer complications amongst 
residual neurocytomas treated with SRS [10]. The authors cautioned that the available 
evidence is mostly low-level, and suggest that the risks and benefits of both approaches 
continue to be weighed patient-by-patient. We agree that more prospective data would be 
helpful.
Based on 20 years of experience, we offer several treatment recommendations. We agree that 
maximal safe resection should remain first line therapy. Postoperatively, MIB-1 label and 
evidence of tumor atypia should influence which patients are considered for adjuvant 
therapy. Our findings support the use of a MIB-1 label of 4 % as a guideline for atypical 
tumors and we recommend multi-disciplinary discussions for patients with MIB-1 staining 
in this range. Based on our small cohort we also found that the addition of adjuvant RT may 
reduce the odds of disease progression for incompletely resected patients. Finally, SRS may 
be an effective salvage modality, particularly for patients with small recurrences.
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Fig. 1. 
Representative neurocytoma MRI imaging findings. a T2 weighted imaging of a 44-year-old 
male found to have an 8.6 × 7.2 cm heterogeneous right lateral ventricle mass; 
predominantly isointense on T2 weighted imaging with no significant enhancement on post-
contrast series. b T2 FLAIR imaging of a 23-year-old male found to have a heterogeneous 
lobulated mass with a mildly enhancing component and other non-enhancing components 
extending superiorly from the suprasellar cistern. c T2 FLAIR imaging of a 20-year-old 
female found to have a 3.4 × 2.5 cm highly cellular lobulated nonenhancing intraventricular 
mass attached to the anterior portion of the septum pellucidum
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Fig. 2. 
PFS based on tumor and clinical characteristics. a Two-year PFS was 82 % for tumors >4.1 
cm versus 75 % for tumors ≤4.1 cm, with a hazard ratio of 1.2 (CI 0.37–3.6, p = 0.80). b 
Two-year PFS was 83 % for >80 % resection and 67 % for ≤80 % resection, with a hazard 
ratio of 0.67 (CI 0.23–2.0, p = 0.47). c Two-year PFS was 90 % for MIB-1 labeling ≤4 and 
48 % for MIB-1 labeling >4 %, with a hazard ratio of 0.18, (CI 0.036–0.44, p = 0.0026). d 
Two-year PFS was 100 % for patients with STR plus adjuvant radiation versus 70 % for 
patients who underwent STR but did not undergo post-op radiation, with an undefined 
hazard ratio since we did not achieve events in greater than 50 % of relevant patients. 
However, the addition of adjuvant radiation significantly improved overall PFS (p = 0.049)
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Table 1
Demographic and treatment characteristics
Entire cohort Stable after initial treatment Recurrent or progressive tumor
All patients 28 15 (54 %) 13 (46 %)
Age at Dx (n = 28)
 Mean (range) 30 (5–61) 31 (20–53) 28 (5–61)
Gender (n = 28)
 Male 15 (54 %) 10 5
 Female 13 (46 %) 5 8
Size by MRI imaging (largest dimension in cm) (n = 27)
 Mean (range) 4.4 (0.8–8.6) 4.1 (0.8–7.0) 4.8 (2.5–8.6)
 Median 4.1 4.1 4.4
Resection extent ± adjuvant radiotherapy (n = 28)
 GTR (all) 9 5 4
 GTR + adjuvant RT 1 1 0
 GTR – adjuvant RT 8 4 4
 STR (all) 19 10 9
 STR + adjuvant RT 3 3 0
 STR – adjuvant RT 16 7 9
Tumor MIB-1 index (percentage) (n = 24)
 Mean (range) 3.5 (0.5–7.7) 2.7 (1.0–7.0) 4.5 (0.5–7.7)
 Median 3.2 2.0 4.8
 Required VP shunting 11 (38 %) 5 6
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